<DOC>
	<DOCNO>NCT00068770</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzymes necessary growth . It yet know whether effectiveness celecoxib treat glioblastoma multiforme decrease patient receive anticonvulsant drug undergo radiation therapy . PURPOSE : Phase II trial study effectiveness celecoxib treat patient receive anticonvulsant drug undergo radiation therapy newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Celecoxib Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs Undergoing RT</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect hepatic enzyme-inducing drug , anticonvulsant , pharmacokinetics celecoxib patient newly diagnose glioblastoma multiforme undergo radiotherapy . - Determine effect steroids pharmacokinetics celecoxib patient . Secondary - Determine safety celecoxib patient . - Determine duration survival patient treat regimen . OUTLINE : This multicenter study . Patients assign 1 2 group base anticonvulsant therapy . - Group A : Patients treat follow anticonvulsant drug induce hepatic metabolic enzyme : - Phenytoin - Carbamazepine - Phenobarbital - Primidone - Oxcarbazepine - Group B : Patients treat follow anticonvulsant drug cause modest induction hepatic metabolic enzyme OR anticonvulsant drug : - Gabapentin - Lamotrigine - Valproic acid - Levetiracetam - Tiagabine - Topiramate - Zonisamide - Felbamate - Induction therapy : Patients group receive oral celecoxib twice* daily week 1-11 undergo radiotherapy 5 day week week 2-7 . - Maintenance therapy : Patients receive oral celecoxib twice daily . Courses repeat every 4 week absence disease progression unacceptable toxicity . NOTE : *Patients receive 1 dose first day celecoxib administration . Patients follow every 2 month . PROJECTED ACCRUAL : A total 44 patient ( 22 per group ) accrue study within approximately 8 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme Supratentorial Grade IV astrocytoma PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Renal Creatinine great 1.7 mg/dL Creatinine clearance least 60 mL/min No prior renal toxicity nonsteroidal antiinflammatory drug Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Mini mental score least 15 No history peptic disease No serious concurrent infection No medical illness would preclude study participation No malignancy within past 5 year except curatively treat carcinoma situ basal cell skin cancer No allergy sulfonamide Able tolerate cyclooxygenase2 ( COX2 ) inhibitor PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy biologic agent malignancy , include follow : Immunotoxins Immunoconjugates Antisense agent Peptide receptor antagonist Interferons Interleukins Tumorinfiltrating lymphocyte Lymphokineactivated killer cell Gene therapy No concurrent prophylactic growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy No prior chemotherapy malignancy Endocrine therapy No prior hormonal therapy malignancy Prior glucocorticoid therapy allow Concurrent corticosteroid allow provide dose increase within past 5 day Radiotherapy No prior radiotherapy malignancy Surgery Recovered prior surgery Other At least 1 week since prior fluconazole More 10 day since prior anticonvulsant drug induce hepatic metabolic enzyme ( Group A ) No prior therapy malignancy No concurrent enrollment another therapeutic clinical trial No concurrent fluconazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>